Pharmaceutical
Human APIs Powder
- Respiratory Drugs Raw Material
- Antiviral Antibacterial
- Antipyretic Analgesics
- Antihistamine Drugs
- Antineoplastic
- Cosmetic Raw Material
OEM & ODM
Veterinary raw materials
Phone: 86-29-89601602
E-mail: sales28@interlgroup.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
bimatoprost raw Powder CAS 155206-00-1 bimatoprost
Product Overview:
Bimaprost is a prostaglandin drug that was first used to treat eye diseases such as glaucoma under the name Lumigan. However, in the course of treatment, patients unexpectedly found that the diameter, length and density of their eyelashes have significantly increased. After that, Bimaprost was used in clinical trials for eyelash beauty, and its huge effect on eyelash thickening and densification directly led to the launch of Lattise, which was approved by the US FDA in December 2008 and became a professional product for blackening and thickening eyelashes
bimatoprost raw Powder CAS 155206-00-1 bimatoprost Attributes
CAS:155206-00-1
MF:C25H37NO4
MW:415.57
EINECS:642-890-9
Specification: 99% min bimatoprost
Sample:bimatoprost Powder
Packaging:1kg/bag, 25kg/drum
Brand: Raw Materials
Appearance:white
Storage: Cool Dry Place
Shelf Life: 2 Years
Test Method: HPLC
bimatoprost raw Powder CAS 155206-00-1 bimatoprost Details
bimatoprost Usage and Synthesis.
Olaparib effectively acts on Brca1; p53 for breast tumors (intraperitoneally injected at a dose of 50mg/kg daily), but against HR deficient Ecad; p53 has no effect on breast tumors. Olaparib had no dose-limiting toxicity in tumor-carrying mice. Olaparib is already used to treat tumors with BRCA mutations, such as ovarian, breast, and prostate cancers. In addition, Olaparib was selective in inhibiting ATM-deficient tumor cells, suggesting that Olaparib could be used as a potential agent for treating ATM-mutated lymphoid tumors.
Uses of bimatoprost.
Olaparib is a PARP inhibitor that also acts on BRCA1 or BRCA2 mutations. Olaparib has little effect on anchor-1, and IC50 value is greater than that of OLaparib. The concentration of Olaparib at 30-100nM acts on SW620 cells and inactivates PARP-1. Compared with BRCA1 and BRCA2-sufficient cell lines (Hs578T,MDA-MB-231,T47D), BRCA1-deficient cell lines (MDA-MB-463[1] and HCC1937) were over-sensitive to Olaparib, which inhibited PARP and blocked base excisation repair. Resulting in strong sensitivity of KB2P cells to Olaparib. The result is a shift from a single strand break to a double strand break during DNA replication, thus activating the BRCA2-dependent recombination pathway.
Preparation of bimatoprost.
Product Method of bimatoprost.
